Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis

Description: Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, “Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis”. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Novavax, a clinical stage biopharmaceutical company, is focused on developing vaccines against diseases such as influenza and respiratory syncytial virus infection. The company employs VLP nanotechnology as the foundation of its vaccine portfolio. Novavax's VLP vaccine is expected to be the second recombinant vaccine against influenza available within the US market, shortly after PSC's FluBlok. Novavax also has multiple development agreements with companies such as GE Healthcare and LG Life Sciences as well as government entities such as the US Office of Biomedical Advanced Research and Development Authority (BARDA).

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Influenza VLP Vaccine including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Influenza VLP Vaccine from 2012 to 2022.
- Sales information covered for the US.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Influenza VLP Vaccine performance
- Obtain sales forecast for Influenza VLP Vaccine from 2012 to 2022 in the US.

Contents

1 1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Symptoms
3.3 Prognosis
4 Disease Management
4.1 Influenza Vaccination Policy
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.1 Overview
6.2 Unmet Needs
6.2.1 Higher Level of Patient Awareness
6.2.2 Increased Efficacy in the Elderly and Young Children (<2 years old)
6.2.3 Improved Vaccine Side-Effect Profiles
6.2.4 More Efficient Vaccine Manufacturing Process
6.2.5 More Cost-Effective Vaccines
6.3 Gap Analysis
6.4 Opportunities
6.4.1 Expanded Breadth of Protection Against Viral Strains
6.4.2 Increased Duration of Protection
6.4.3 T-cell Involvement
7 Pipeline Assessment
7.1 Overview
7.2 Promising vaccines in clinical development
7.2.1 Influenza VLP Vaccine
8 Appendix
8.1 Bibliography
8.2 Abbreviations
8.3 Methodology
8.4 Forecasting Methodology
8.4.1 Vaccine Coverage
8.4.2 Vaccines Included
8.4.3 The price that Influenza Vaccine Tender System Assumptions
8.4.4 General Pricing Assumptions
8.4.5 Pricing of Pipeline Agents
8.5 Physicians and Specialists Included in this Study
8.6 Primary Research - Prescriber Survey
8.7 About the Authors
8.7.1 Authors
8.7.2 Global Head of Healthcare
8.8 About Us
8.9 Contact Us
8.10 Disclaimer

1.1 List of Tables
Table 1: Notable Influenza Pandemics
Table 2: Symptoms of Influenza
Table 3: Influenza Vaccination Recommendation Committees by Country
Table 4: Most Administered Influenza Vaccines by Country in the Global Markets, 2012
Table 5: Leading Influenza Vaccines, 2012
Table 6: Overall Unmet Needs - Current Level of Attainment
Table 7: Clinical Unmet Needs - Gap Analysis, 2012
Table 8: Seasonal Influenza Vaccines - Phase Pipeline, 2012
Table 9: Product Profile - FluBlok
Table 10: Influenza VLP Vaccine SWOT Analysis, 2012
Table 11: Global Sales Forecasts ($m) for Influenza VLP Vaccine, 2012-2022
Table 12: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Influenza Virus Structure
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Seasonal Influenza, 2012-2022
Ordering:

Order Online - http://www.researchandmarkets.com/reports/2368601/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2368601/">http://www.researchandmarkets.com/reports/2368601/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SC6IJX6P</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3495</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 6990</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10485</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World